Andrew J. Hale, MD, is an infectious disease physician at the University of Vermont Medical Center and an assistant professor of medicine at Larner College of Medicine at the University of Vermont in Burlington.
Reduced-Dose Trimethoprim-Sulfamethoxazole Effective in Treating Mild to Moderate Pneumocystis jirovecii Pneumonia
Here is a review of using this therapy in this patient population.
Is There a Better Choice Than TMP-SMX to Treat Stenotrophomonas maltophilia Infections?
Mono or Combo? Exploring the Role of Combination Antimicrobial Therapies for Invasive Carbapenem-Resistant Gram-Negative Infections
Improving Vaccine Uptake in a Cohort of Patients With Asplenia
This is one of the first studies examining the effect of a dedicated postsplenectomy comprehensive clinic.
Where to Treat Uncomplicated HCV? Assessing the Impact of Shifting Care From Specialists to PCPs
One promising proposal to greatly increase access to DAA HCV therapy is to keep this treatment with appropriately trained PCPs, in contrast with referring patients to infectious disease, gastroenterology, or hepatology subspecialists.
Optimal Vancomycin Dosing in Obese Patients: Moving Toward the AUC
This In the Literature piece explores if we can mitigate some of the adverse reactions that are being seen in obese patients who receive vancomycin through AUC-dosing.
Partial Oral Treatment of Infective Endocarditis Can Be Effective in Select Patients: Review of the POET Trial
By itself, the POET trial should not fundamentally change the current approach to infective endocarditis treatment.
2 Clarke Drive Cranbury, NJ 08512